Robert E. Conway Elected Chairman of ARCA biopharma Board of Directors
WESTMINSTER, Colo. -- June 9, 2014
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing
genetically-targeted therapies for cardiovascular diseases, today announced
that Robert E. Conway, has been elected Chairman of the Company’s Board of
Directors. He serves on the Audit and Compensation Committees of the Board of
Mr. Conway has over 30 years of executive leadership experience in the
pharmaceutical and biotechnology industries. Mr. Conway served as the Chief
Executive Officer and member of the Board of Directors of Array BioPharma from
1999 to 2012. Array is a biopharmaceutical company focused on the discovery,
development and commercialization of targeted small molecule drugs to treat
patients afflicted with cancer and inflammatory diseases. Prior to joining
Array, Mr. Conway was the Chief Operating Officer and Executive Vice President
of Hill Top Research, Inc., a clinical research services company, from 1996 to
1999. He also held various executive positions for Corning Inc. including
Corporate Vice President and General Manager of Corning Hazleton, Inc., a
contract research organization. Mr. Conway serves as the Chairman of Wall
Family Enterprise, a leading library and education supplies company. He is on
the Board of Directors of eResearch Technology, Inc. In addition, Mr. Conway
is a member of the Strategic Advisory Committee of Genstar Capital, LLC.
“Bob’s experience and leadership are a tremendous asset to ARCA,” said Dr.
Michael R. Bristow, President and Chief Executive Officer of ARCA. “With his
significant experience in leading both drug development efforts and companies
in the biopharmaceutical sector, Bob’s input and guidance be valuable to the
ARCA Board as we continue the development of Gencaro and look to deliver value
to our stockholders.”
“I am honored to accept this role with the ARCA Board of Directors,” said Mr.
Conway. “This is an exciting time for the organization with the GENETIC-AF
trial under way. We believe there is an unmet medical need for new atrial
fibrillation treatments. The GENETIC-AF trial, conducted with the
collaboration of Medtronic, will hopefully provide important new data for the
atrial fibrillation community.”
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies for
cardiovascular diseases. The Company's lead product candidate, Gencaro^TM
(bucindolol hydrochloride), is an investigational, pharmacologically unique
beta-blocker and mild vasodilator being developed for atrial fibrillation.
ARCA has identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential to be the
first genetically-targeted atrial fibrillation prevention treatment. ARCA has
a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For
more information please visit www.arcabiopharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of the
safe harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements regarding,
potential timing for patient enrollment in the GENETIC-AF trial, the
sufficiency of the Company’s capital to support its operations, the potential
for genetic variations to predict individual patient response to Gencaro,
Gencaro’s potential to treat atrial fibrillation, future treatment options for
patients with atrial fibrillation, and the potential for Gencaro to be the
first genetically-targeted atrial fibrillation prevention treatment. Such
statements are based on management's current expectations and involve risks
and uncertainties. Actual results and performance could differ materially from
those projected in the forward-looking statements as a result of many factors,
including, without limitation, the risks and uncertainties associated with:
the Company's financial resources and whether they will be sufficient to meet
the Company's business objectives and operational requirements; results of
earlier clinical trials may not be confirmed in future trials, the protection
and market exclusivity provided by the Company’s intellectual property; risks
related to the drug discovery and the regulatory approval process; and, the
impact of competitive products and technological changes. These and other
factors are identified and described in more detail in ARCA’s filings with the
SEC, including without limitation the Company’s annual report on Form 10-K for
the year ended December 31, 2013, and subsequent filings. The Company
disclaims any intent or obligation to update these forward-looking statements.
ARCA biopharma, Inc.
Investor & Media Contact:
Derek Cole, 720-940-2163
Press spacebar to pause and continue. Press esc to stop.